Aspergillus sensitization or carriage in cystic fibrosis patients

Pediatric Infectious Disease Journal

Volumn 33, Issue 7, 2014, Pages 680-686

  Fillaux, Judith ^a,b   Brémont, François ^c,d   Murris, Marlène ^d,e   Cassaing, Sophie ^a,b   Tétu, Laurent ^d,e   Segonds, Christine ^a   Pipy, Bernard ^b   Magnaval, Jean François ^a  

^a CHU PURPAN   (France)

^b UMR 152 IRD Universite Paul Sabatier   (France)

^c HÔPITAL DES ENFANTS   (France)

^d Service de Pneumologie   (France)

^e SERVICE DE PNEUMOLOGIE   (France)

Author keywords

cystic fibrosis; fungal infection; predictive factors; sensitization

Indexed keywords

AZITHROMYCIN; CATALASE; IMMUNOGLOBULIN E; FUNGUS ANTIBODY;

ARTICLE; ASPERGILLUS FUMIGATUS; BODY MASS; CHILD; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; FUNGAL COLONIZATION; GENE MUTATION; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SENSITIZATION; SPUTUM; ADOLESCENT; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; BLOOD; COMPLICATION; HETEROZYGOTE; IMMUNOLOGY; INFANT; ISOLATION AND PURIFICATION;

ADOLESCENT; ANTIBODIES, FUNGAL; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; ASPERGILLUS FUMIGATUS; CARRIER STATE; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; HUMANS; IMMUNOGLOBULIN E; INFANT; MALE;

EID: 84902550971     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000231     Document Type: Article

References (54)

1. Yankaskas JR, Marshall BC, Sufian B, et al. Cystic fibrosis adult care: consensus conference report. Chest. 2004;125(suppl 1):1S-39S.
2. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168:918-951.
3. Sagel SD, Gibson RL, Emerson J, et al.; Inhaled Tobramycin in Young Children Study Group; Cystic Fibrosis Foundation Therapeutics Development Network. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr. 2009;154:183-188.
4. Bellis G, Cazès MH, Fuhrman C, et al. Cystic fibrosis French Registry - Report 2006. Paris: Vaincre la Mucoviscidose & Ined; 2009.
5. Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 2002;110:685-692.
6. Mastella G, Rainisio M, Harms HK, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. Eur Respir J. 2001;17:1052-1053.
7. Thia LP, Balfour Lynn IM. Diagnosing allergic bronchopulmonary aspergillosis in children with cystic fibrosis. Paediatr Respir Rev. 2009;10:37-42.
8. Skov M, McKay K, Koch C, et al. Prevalence of allergic bronchopulmonary aspergillosis in cystic fibrosis in an area with a high frequency of atopy. Respir Med. 2005;99:887-893.
9. Fillaux J, Brémont F, Murris M, et al. Assessment of Aspergillus sensitization or persistent carriage as a factor in lung function impairment in cystic fibrosis patients. Scand J Infect Dis. 2012;44:842-847.
10. Amin R, Dupuis A, Aaron SD, et al. The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest. 2010;137:171-176.
11. Shoseyov D, Brownlee KG, Conway SP, et al. Aspergillus bronchitis in cystic fibrosis. Chest. 2006;130:222-226.
12. Baxter CG, Moore CB, Jones AM, et al. IgE-mediated immune responses and airway detection of Aspergillus and Candida in adult cystic fibrosis. Chest. 2013;143:1351-1357.
13. Máiz L, Cuevas M, Quirce S, et al. Serologic IgE immune responses against Aspergillus fumigatus and Candida albicans in patients with cystic fibrosis. Chest. 2002;121:782-788.
14. Bargon J, Dauletbaev N, Köhler B, et al. Prophylactic antibiotic therapy is associated with an increased prevalence of Aspergillus colonization in adult cystic fibrosis patients. Respir Med. 1999;93:835-838.
15. Jubin V, Ranque S, Stremler Le Bel N, et al. Risk factors for Aspergillus colonization and allergic bronchopulmonary aspergillosis in children with cystic fibrosis. Pediatr Pulmonol. 2010;45:764-771.
16. Ritz N, Ammann RA, Aebischer CC, et al. Risk factors for allergic bronchopulmonary aspergillosis and sensitisation to Aspergillus fumigatus in patients with cystic fibrosis. Eur J Pediatr. 2005;164:577-582.
17. Baxter CG, Dunn G, Jones AM, et al. Novel immunologic classification of aspergillosis in adult cystic fibrosis. J Allergy Clin Immunol. 2013;132: 560-566.e10.
18. Farrell PM, Rosenstein BJ, White TB, et al.; Cystic Fibrosis Foundation. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr. 2008;153:S4-S14.
19. Gibson LE, Cooke RE. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics. 1959;23:545-549.
20. de Gracia J, Mata F, Alvarez A, et al. Genotype-phenotype correlation for pulmonary function in cystic fibrosis. Thorax. 2005;60:558-563.
21. McKone EF, Emerson SS, Edwards KL, et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet. 2003;361:1671-1676.
22. Rowntree RK, Harris A. The phenotypic consequences of CFTR mutations. Ann Hum Genet. 2003;67(pt 5):471-485.
23. Zielenski J. Genotype and phenotype in cystic fibrosis. Respiration. 2000;67:117-133.
24. Castellani C, Cuppens H, Macek M Jr, et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros. 2008;7:179-196.
25. Cole TJ, Bellizzi MC, Flegal KM, et al. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ. 2000;320:1240-1243.
26. INPES. Courbes enfants 2006. Available at: http://www.inpes.sante. fr/50000/pdf/courbes-enfants.pdf. Accessed May 27, 2009.
27. Rolland-Cachera MF, Cole TJ, Sempé M, et al. Body Mass Index variations: centiles from birth to 87 years. Eur J Clin Nutr. 1991;45:13-21.
28. Wang X, Dockery DW, Wypij D, et al. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol. 1993;15:75-88.
29. Klich MA. Identification of Common Aspergillus Species. Utrecht: CBS; 2002.
30. Société Française de Microbiologie. Examen bactériologique des sécrétions bronchopulmonaires chez un patient mucoviscidosique. In: Vivactis Plus ed. Rémic. Paris; Vivactis Plus; 2007:35-38.
31. Döring G, Conway SP, Heijerman HG, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J. 2000;16:749-767.
32. Knudsen PK, Olesen HV, Høiby N, et al.; Scandinavian CF Study Consortium (SCFSC). Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden. J Cyst Fibros. 2009;8:135-142.
33. Lee TW, Brownlee KG, Conway SP, et al. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros. 2003;2:29-34.
34. Borron F, Persat F, Borel MA, Mojon M. Evaluation de l'immunoé lectrophorèse rapide Paragon (P) (Beckman) appliquée au sérodiagnostic aspergillaire. J Mycol Med. 1994;4:221-225.
35. Tran-van-Ky P, Torck C, Vaucelle T, et al. [Comparative study on immunoelectrophoregrams of enzymes of the antigenic extract of Aspergillus fumigatus revealed by experimental serums and serums of patients with aspergillosis]. Sabouraudia. 1969;7:73-84.
36. Bremont F, Recco P, Linas MD, et al. Mycoses bronchopulmonaires et mucoviscidose. Revue Française des Laboratoires. 1993;249:115-118.
37. Brémont F, Rittié JL, Rancé F, et al. [Allergic bronchopulmonary aspergillosis in children]. Arch Pediatr. 1999;6(suppl 1):87S-93S.
38. Langholz B, Jiao J. Computational methods for case-cohort studies. Computat Stat Data An. 2007;51:3737-3748.
39. Stevens DA, Moss RB, Kurup VP, et al.; Participants in the Cystic Fibrosis Foundation Consensus Conference. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis. 2003;37 (suppl 3):S225-S264.
40. Babu KS, Kastelik J, Morjaria JB. Role of long term antibiotics in chronic respiratory diseases. Respir Med. 2013;107:800-815.
41. Clement A, Tamalet A, Leroux E, et al. Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial. Thorax. 2006;61:895-902.
42. Ratjen F, Saiman L, Mayer-Hamblett N, et al. Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa. Chest. 2012;142:1259-1266.
43. Saiman L, Anstead M, Mayer-Hamblett N, et al.; AZ0004 Azithromycin Study Group. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2010;303:1707-1715.
44. Saiman L, Mayer-Hamblett N, Anstead M, et al.; AZ0004 Macrolide Study Team. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatr Pulmonol. 2012;47:641-648.
45. Eaton TE, Weiner Miller P, Garrett JE, et al. Cystic fibrosis transmembrane conductance regulator gene mutations: do they play a role in the aetiology of allergic bronchopulmonary aspergillosis? Clin Exp Allergy. 2002;32:756-761.
46. Luisetti M, Pignatti PF. Genetics of idiopathic disseminated bronchiectasis. Semin Respir Crit Care Med. 2003;24:179-184.
47. Miller PW, Hamosh A, Macek M Jr, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis. Am J Hum Genet. 1996;59:45-51.
48. Calera JA, Paris S, Monod M, et al. Cloning and disruption of the antigenic catalase gene of Aspergillus fumigatus. Infect Immun. 1997;65:4718-4724.
49. Paris S, Wysong D, Debeaupuis JP, et al. Catalases of Aspergillus fumigatus. Infect Immun. 2003;71:3551-3562.
50. Konstan MW, Morgan WJ, Butler SM, et al.; Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr. 2007;151:134-9, 139.e1.
51. Kraemer R, Baldwin DN, Ammann RA, et al. Progression of pulmonary hyperinflation and trapped gas associated with genetic and environmental factors in children with cystic fibrosis. Respir Res. 2006;7:138.
52. Burggraeve N, Branger B, Dabadie A, et al. [Longitudinal evaluation of pulmonary function tests in children with newborn screening for cystic fibrosis. Relationships with pulmonary infection. Study of 40 children undergoing 744 pulmonary function tests]. Arch Pediatr. 2007;14:864-869.
53. Bakare N, Rickerts V, Bargon J, et al. Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis. Mycoses. 2003;46:19-23.
54. Borman AM, Palmer MD, Delhaes L, et al. Lack of standardization in the procedures for mycological examination of sputum samples from CF patients: a possible cause for variations in the prevalence of filamentous fungi. Med Mycol. 2010;48 (suppl 1):S88-S97.